BofA analyst Graham Parry downgraded GSK to Underperform from Neutral with a price target of 1,450 GBp, down from 1,640 GBp. The analyst calls GSK his least preferred major European pharma name heading into 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK price target lowered to 1,550 GBp from 1,975 GBp at Citi
- AnaptysBio, GSK announces Phase 3 RUBY trial results for JEMPERLI
- GSK reports EMA accepts marketing authorization application for momelotinib
- GSK’s phase 3 trial of Jemperli meets primary endpoint
- GSK price target lowered to 1,535 GBp from 1,650 GBp at Morgan Stanley